An interventional study of DNA care pathway in Fall, Fall Accident and Poly Pharmacy, sponsored by Florida Atlantic University. Recruiting at 1 site in United States. Open to participants aged 65 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Florida Atlantic University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States — 13 open to participants now, 18 under way, 2 of them phase 3. Drug-Related Side Effects and Adverse Reactions · United States.
Among the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, this one is the 9th largest by planned enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2026, is one of 38 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 137th registered.
449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.
Browse Drug-Related Side Effects and Adverse Reactions studies →13 of the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States are open now. Recruiting first, the newest first:
Texas A&M University · Sites in United States
Ages 18–100
St. Jude Children's Research Hospital · Sites in United States
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
Texas A&M University · Sites in United States
Ages 18+
Brigham and Women's Hospital · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.
This study: 65 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 14 · Phase 4 11
First in 1993; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 108 across 262 interventional studies indexed under Drug-Related Side Effects and Adverse Reactions.
Median enrollment 96 across the 95 interventional studies, 200 across the 35 observational. Of the 102 that completed or were terminated, 26 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 140 have an industry lead sponsor. The 10 most frequent:
Florida Atlantic University is the lead sponsor of 36 studies on the registry; 7 are open to participants now.
Florida Atlantic University has 1 study filed under Drug-Related Side Effects and Adverse Reactions — fewer than ten, so there is no comparison to draw.
6 of the studies in Drug-Related Side Effects and Adverse Reactions with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05358535Phase 3University of Texas Southwestern Medical CenterPropofol and Etomidate Admixtures Comparisons Trial (PEAC Trial) | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT06219720Texas A&M UniversityThe Texas Interprofessional Pharmacogenomics (IPGx) | 2026-11 |
| NCT07169851Eli Lilly and CompanyA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | 2026-12 |
| NCT05838638University of Central FloridaSerious Gaming for Chemotherapy-induced Nausea and Vomiting | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications.
The main questions it aims to answer are:
Researchers will compare two groups:
Participants will:
Approximately 1,000 participants will take part, with follow-up lasting about 6-7 months.
Background and Rationale Medication prescribing is one of the most common medical interventions. In the U.S., 81% of adults report taking at least one medication in the past week, and 50% take prescription medications. Among older adults, 39% meet the criteria for polypharmacy, defined as the use of five or more chronic medications.
Polypharmacy is strongly associated with adverse drug events (ADEs). Each day, approximately 750 older adults in the U.S. are hospitalized due to ADEs, with half of these patients taking five or more medications. Nearly 60% of older adults are prescribed at least one potentially unnecessary medication.
Traditional prescribing often follows a "one-size-fits-all" approach, which does not account for genetic differences in how individuals metabolize drugs. These genetic variations can lead to ineffective treatment or harmful side effects. Pharmacogenomic-guided prescribing may provide a safer, more personalized approach by identifying drug-gene interactions and tailoring medication choices.
Falls and Medication Safety Falls are one of the most serious and preventable ADEs among older adults. Falls are the leading cause of injury-related morbidity and mortality in older populations, with over 700,000 hospital falls in the U.S. annually. Polypharmacy, especially the use of fall-risk-increasing drugs (FRIDs), contributes substantially to this problem.
By integrating pharmacogenomic testing into medication management, clinicians may be able to reduce fall-related ADEs and improve overall prescribing safety.
Study Objectives and Aims The Geriatric Emergency Department Pharmacologic Harm Prevention Project (The GREAT PHARM) seeks to evaluate whether pharmacogenomic-guided prescribing can reduce ADEs and falls among older adults.
Aim 1: Compare the incidence of recurrent falls, ADE-related emergency department (ED) visits, and all-cause mortality in patients receiving pharmacogenomic-guided medication optimization versus usual care.
Secondary Aim 1: Assess barriers to implementing pharmacogenomic-based prescribing. Aim 2: Determine the prevalence of harmful gene-drug interactions and abnormal drug levels in older adults presenting to the ED after a fall.
Aim 3: Compare self-reported wellbeing and health satisfaction between patients who receive pharmacogenomic-guided prescribing and those receiving usual care.
Study Design
Randomization: Participants will be randomized (via REDCap) into two study arms:
Interventions
All participants will:
Outcome Measures
Primary Outcomes:
Secondary Outcomes:
Duration of Participation Each participant will be followed for approximately 6-7 months, with ongoing monitoring through phone calls, calendars, and medical record review.
Significance This trial will evaluate whether personalized prescribing guided by DNA testing can reduce medication-related harm, prevent recurrent falls, and improve overall quality of life for older adults. If successful, the study will provide strong evidence for integrating pharmacogenomic-guided prescribing into standard clinical care for geriatric patients at risk of medication-related harm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pharmacogenomic test results will be transmitted to the participant's primary care physician to support medication optimization and prescribing decisions. Follow-up assessments will be conducted by telephone approximately 14 days after enrollment and then monthly for six months. These structured interviews will capture information on falls, fall-related injuries, medication changes, adverse drug effects, and new medical conditions. Participants will also complete a monthly calendar to document medication changes, falls, and fall-related injuries. Medical records from the participant's primary care physician will be reviewed for corroborating information on falls, fall-related injuries, medication changes, medication-related side effects, and newly diagnosed medical problems.
Other: DNA care pathway
Participants randomized to the current Emergency Department care pathway will continue to receive standard prescribing practices without immediate use of pharmacogenomic results. Follow-up assessments will occur by telephone approximately 14 days after enrollment and then monthly for six months. These calls will collect data on falls, fall-related injuries, medication changes, adverse drug effects, and new medical conditions. Participants will also complete a monthly calendar documenting medication changes, falls, and fall-related injuries. Medical records from the participant's primary care physician will be reviewed to identify additional falls, injuries, medication changes, side effects, and new medical problems. At the conclusion of the study, pharmacogenomic testing results will be provided to the participant's primary care physician to support future prescribing decisions.
Pharmacogenomic test results will be transmitted to the participant's primary care physician to support medication optimization and prescribing decisions. Follow-up assessments will be conducted by telephone approximately 14 days after enrollment and then monthly for six months. These structured interviews will capture information on falls, fall-related injuries, medication changes, adverse drug effects, and new medical conditions. Participants will also complete a monthly calendar to document medication changes, falls, and fall-related injuries. Medical records from the participant's primary care physician will be reviewed for corroborating information on falls, fall-related injuries, medication changes, medication-related side effects, and newly diagnosed medical problems.
Recurrent falls -self reported and chart review
Incidence of recurrent falls during 6-7 months of follow-up. Around the fourteenth day of the study and then once a month for the following six months, participants will receive a follow-up phone call to assess any falls that may have occurred. In addition, each participant will receive a calendar to record falls during the month. At six-month, the primary care physician medical records will be reviewed to check for any additional falls.
Time frame: 6-7 months
Incidence of ADE-related ED visits- self reported and chart review
Incidence of ADE-related ED visits during 6-7 months of follow-up. Around the fourteenth day of the study and then once a month for the following six months, participants will receive a follow-up phone call to assess any ADE-related ED visits that may have occurred. At six-month, the primary care physician medical records will be reviewed to check for any additional ADE-related ED visits.
Time frame: Time Frame: 6-7 months
All-cause mortality - Florida Death Registry
During 6-7 months of follow-up. All participants will be cross-referenced with the Florida Death Registry to identify mortality outcomes
Time frame: Time Frame: 6-7 months
Plan to share: No — No current plan to do it
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 71 non-industry interventional studies with no phase under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 23 months is below that.
Counting every sponsor, half of 73 studies reached it within 26 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Drug-Related Side Effects and Adverse Reactions →
Florida Atlantic University